38
Participants
Start Date
January 21, 2019
Primary Completion Date
November 2, 2021
Study Completion Date
November 2, 2021
Ad26.RSV.preF
Ad26.RSV.preF will be administered as IM injection at a dose of 2.5\*10\^10 vp.
Placebo
Placebo will be administered as IM injection of sterile 0.9 percent (%) saline for injection.
Nimenrix
Nimenrix will be administered as 0.5 milliliter (mL) solution for IM injection.
Murdoch Children's Research Institute, Parkville
Barwon Health, Geelong
Telethon Kids Institute, Nedlands
Sachsska barn-och ungdomssjukhuset, Stockholm
Hosp. Clinico Univ. de Santiago, Santiago de Compostela
Turun rokotetutkimusklinikka, Turku
Hosp. Gral. Univ. Gregorio Maranon, Madrid
Hosp. Univ. 12 de Octubre, Madrid
Hosp. Univ. La Paz, Madrid
Tampereen rokotetutkimusklinikka, Tampere
Norrlands Universitetssjukhus, Umeå
Complexo Hospital de Clinicas - UFPR, Curitiba
Hospital Pequeno Principe, Curitiba
Irmandade Santa Casa de Misericordia de Porto Alegre, Porto Alegre
Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS, Porto Alegre
Dalhousie University, Halifax
Children's Hospital of Eastern Ontario, Ottawa
McGill University Health Centre - Vaccine Study Centre, Pierrefonds
CHU de Quebec Universite Laval, Québec
Järvenpään rokotetutkimusklinikka, Järvenpää
Jerzy Brzostek Prywatny Gabinet Lekarski, Dębica
Szpital im Swietej Jadwigi Slaskiej Oddzial Pediatryczny z Pododdzialem Niemowlecym, Trzebnica
Imperial College London, London
Royal Manchester Children's Hospital, Manchester
University Hospital Southampton NHS Foundation Trust, Southampton
Janssen Vaccines & Prevention B.V.
INDUSTRY